OSI-906 (Linsitinib)

OSI-906 (Linsitinib)は一種の選択性的なIGF-1R阻害剤で、無細胞実験で、IC50値が35 nMです。OSI-906 (Linsitinib)はInsRを適合に抑制して、このIC50値が75 nMになリますが、Abl、ALK、BTK、EGFR、FGFR1/2とPKA等に抑制活性を表しません。臨床3期。

価格 在庫  
USD 214 あり
USD 239 あり
USD 340 あり
USD 907 あり

OSI-906 (Linsitinib) 化学構造
分子量: 421.49

高品質保証

カスタマーフィードバック(3)

MSDS

製品説明

  • Compare IGF-1R Inhibitors
    IGF-1R製品生物活性の比較
  • 研究分野

製品の説明

生物活性

製品説明 OSI-906 (Linsitinib)は一種の選択性的なIGF-1R阻害剤で、無細胞実験で、IC50値が35 nMです。OSI-906 (Linsitinib)はInsRを適合に抑制して、このIC50値が75 nMになリますが、Abl、ALK、BTK、EGFR、FGFR1/2とPKA等に抑制活性を表しません。臨床3期。
ターゲット IGF-1R InsR
IC50 35 nM 75 nM [1]
In vitro試験 OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. [1]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
A4-Fuk M2TG[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTBwMEK4NFYh|ryP M{TmWXNCVkeHUh?=
KS-1 M2PpN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\3SGlEPTB;MD6wN|g{PSEQvF2= NVLnWIFvW0GQR1XS
TE-11 NX;OXFRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXSwe2Y3UUN3ME2wMlA4QDJ{IN88US=> NFXDSW5USU6JRWK=
EW-1 NXrHOnpiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrMOXQ5UUN3ME2wMlA5PTh3IN88US=> MmrZV2FPT0WU
HMV-II MoHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13vO2lEPTB;MD6wPFg1PiEQvF2= M1L4cXNCVkeHUh?=
COLO-205 NWTpSpJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEP1OndKSzVyPUCuNVA1PTRizszN NVXtNZY4W0GQR1XS
ES1 NFnvSnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIW3XplKSzVyPUCuNVA3QTZizszN MlS1V2FPT0WU
GDM-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTBwMUO2O|Ih|ryP NVu3WWk5W0GQR1XS
ML-2 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\YboEyUUN3ME2wMlE2QDl4IN88US=> MonkV2FPT0WU
Saos-2 MoDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPvSZlKSzVyPUCuNVY2OjZizszN MXfTRW5ITVJ?
NCI-H1355 MonkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTBwMUixN|Uh|ryP NXTjXJVvW0GQR1XS
G-401 M{T1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfZbIpKSzVyPUCuNVgzOyEQvF2= NHnrVJNUSU6JRWK=
EW-16 M3f0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHyzb3dKSzVyPUCuNVg4PzdizszN NVzhSG92W0GQR1XS
EW-7 M{fNVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV[0U|V6UUN3ME2wMlE5QDhzIN88US=> M3fqcXNCVkeHUh?=
NCI-H727 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnuyTWM2OD1yLkG5O|k1KM7:TR?= Mm\NV2FPT0WU
LCLC-97TM1 MoLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGm4eWtKSzVyPUCuNlA6PTVizszN MXHTRW5ITVJ?
NCI-H650 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nrUWlEPTB;MD6yNVM5PCEQvF2= NXzpcG56W0GQR1XS
NCI-H2122 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;LTWM2OD1yLkKzNlk6KM7:TR?= MlnBV2FPT0WU
SK-N-DZ M1WyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTBwMkO2PVgh|ryP M4XidHNCVkeHUh?=
HT-29 NF7aUXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDwUIpkUUN3ME2wMlI1OjR6IN88US=> MYXTRW5ITVJ?
LB771-HNC NI\Rc4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;rclZuUUN3ME2wMlI2QTF3IN88US=> M{fxNXNCVkeHUh?=
HT-144 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHX5T2pKSzVyPUCuNlYyQTFizszN NHj1dlZUSU6JRWK=
LAN-6 NUHkVZNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;hNmlEPTB;MD6yOlM1QCEQvF2= MmHEV2FPT0WU
EW-18 M37nfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPlS3NvUUN3ME2wMlI4ODBzIN88US=> MmTYV2FPT0WU
LS-1034 MmjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7FeJl7UUN3ME2wMlI4OTN{IN88US=> M2PQe3NCVkeHUh?=
EW-11 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHu3fIZKSzVyPUCuNlg1OzJizszN MlL6V2FPT0WU
SNU-C1 NHPxcVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrwd2FZUUN3ME2wMlI6OzF|IN88US=> NWDKR3lpW0GQR1XS
RS4-11 NWGy[ZRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vXdmlEPTB;MD6zN|c2QCEQvF2= MUXTRW5ITVJ?
ES4 NEjINYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DrNWlEPTB;MD60NVA{QCEQvF2= M1vxU3NCVkeHUh?=
COLO-320-HSR NXq2NpVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPFTWM2OD1yLkSxN|Y5KM7:TR?= NXzIcVBuW0GQR1XS
NB10 M3XKemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIi5UmtKSzVyPUCuOFU1OzdizszN MlTPV2FPT0WU
BFTC-905 M4H2OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTBwNE[3OVgh|ryP MXTTRW5ITVJ?
A375 NFjRXJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfHSIRKSzVyPUCuOFc3OTdizszN MnnRV2FPT0WU
SJRH30 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWOxVHNIUUN3ME2wMlUxQDJ{IN88US=> M2L0cXNCVkeHUh?=
NOS-1 M3z2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHGbIFMUUN3ME2wMlUzOjZ5IN88US=> NUH5VHdkW0GQR1XS
SIG-M5 NXnNcHNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHuTWM2OD1yLkWzOVU4KM7:TR?= NGfIdHhUSU6JRWK=
DOK MmXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TGTmlEPTB;MD61OVYh|ryP Mmq1V2FPT0WU
NB69 NF3GXHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTBwNUiyOVch|ryP Mln0V2FPT0WU
SK-NEP-1 NHHLZZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXizTFlXUUN3ME2wMlYxOjN4IN88US=> NWXXR2JWW0GQR1XS
SK-MM-2 MmDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPrbow3UUN3ME2wMlY2PDlzIN88US=> NGj0VY5USU6JRWK=
NCI-H358 M3;zOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTBwNkewPFIh|ryP NH\rV2FUSU6JRWK=
RH-1 NXvFZWFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3FU4VtUUN3ME2wMlc1QDV7IN88US=> MXfTRW5ITVJ?
NH-12 M1rsb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLKTWM2OD1yLke2NFQ3KM7:TR?= NYf3W3ZNW0GQR1XS
TE-12 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTnfJVpUUN3ME2wMlc3PDh4IN88US=> NEfJelJUSU6JRWK=
COLO-668 M3PPcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2W0XWlEPTB;MD64OFY3PiEQvF2= MonhV2FPT0WU
PANC-08-13 M{nDSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTBwOE[zO|ch|ryP NG\2T2ZUSU6JRWK=
HCC2998 NYC4[|lzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPCTWM2OD1yLki4NlY{KM7:TR?= NITKN41USU6JRWK=
ABC-1 NGHheFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLrTWM2OD1yLkmwN|UzKM7:TR?= NWe2UGlXW0GQR1XS
ES6 NET2PW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjrW2t3UUN3ME2wMlkyODZ4IN88US=> M3zXeHNCVkeHUh?=
SNU-387 M1z4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTBwOUmzPVMh|ryP M{X6OXNCVkeHUh?=
CMK MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWj0RnZxUUN3ME2wMlk6QTJ7IN88US=> MULTRW5ITVJ?
SJSA-1 M{jEXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jjfGlEPTB;MT6wN|Y2OyEQvF2= M2rKd3NCVkeHUh?=
SIMA Mnz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTFwME[4NlUh|ryP NFHRb4dUSU6JRWK=
ES3 M13RZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTFwMUKyPVch|ryP MWfTRW5ITVJ?
IGROV-1 NFv0UldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXzfWhKSzVyPUGuNVU1PDRizszN NFXheZVUSU6JRWK=
MEL-JUSO NEHV[pNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jq[2lEPTB;MT6xOVc2QSEQvF2= MkflV2FPT0WU
T84 MnjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXYTWM2OD1zLkKwPVE1KM7:TR?= NWn0coNmW0GQR1XS
CAL-85-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTFwMkOxN|gh|ryP NEj4dWRUSU6JRWK=
RD MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjWeIpKSzVyPUGuNlY1PTVizszN NH7zN5BUSU6JRWK=
TE-8 MmfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrPUYNJUUN3ME2xMlMyPDZ{IN88US=> NU\uXlE{W0GQR1XS
L-363 NFTzUXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljMTWM2OD1zLkO0NlA5KM7:TR?= NWW1T3oxW0GQR1XS
EKVX MmrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTaV3NKSzVyPUGuN|Q2PjhizszN NUK0dog2W0GQR1XS
SK-MEL-3 NWj0[45kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XGSWlEPTB;MT60PFU2PiEQvF2= Mn3OV2FPT0WU
TGBC24TKB M1HDR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTPR2ZxUUN3ME2xMlUxOTl|IN88US=> M3u0THNCVkeHUh?=
NCI-H1770 NHvDWllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETvSnBKSzVyPUGuOVEyOTNizszN NFXB[mdUSU6JRWK=
HuH-7 NVzsW4JGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvhUotQUUN3ME2xMlYxODl6IN88US=> Mly3V2FPT0WU
HL-60 NFfMRWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIGxeGRKSzVyPUGuOlY6OjhizszN M2fZNXNCVkeHUh?=
TE-1 NYfve|hOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4eyOWlEPTB;MT63NFk1PSEQvF2= MnTXV2FPT0WU
LC-2-ad MnK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDMTWM2OD1zLkezPFg4KM7:TR?= Mme3V2FPT0WU
LB647-SCLC M1fkfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXkTWM2OD1zLke2OVg{KM7:TR?= MYnTRW5ITVJ?
NCI-H2171 M4fIUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTFwN{e3NVYh|ryP MXzTRW5ITVJ?
SK-PN-DW NU\T[ZVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVm2OGY4UUN3ME2xMlkyOjl6IN88US=> MXTTRW5ITVJ?
MC-IXC MnXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2K4dmlEPTB;MT65PFk5KM7:TR?= NVTVfpRFW0GQR1XS
LS-513 M4LSOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPkTWM2OD1{LkC1N|A2KM7:TR?= MXrTRW5ITVJ?
EW-3 NYLDR21OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTJwMEm4OFQh|ryP MYDTRW5ITVJ?
OPM-2 NXLhW3dST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;2TWM2OD1{LkGwNkDPxE1? NWT0fFNUW0GQR1XS
LP-1 MnG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7hTGRKSzVyPUKuNlU5ODdizszN NH;W[JNUSU6JRWK=
LU-134-A NUHBV49qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3i0RmlEPTB;Mj6yO|ch|ryP M2GwSnNCVkeHUh?=
CP66-MEL MnXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYn2Uo1MUUN3ME2yMlI6ODF2IN88US=> M3;2[XNCVkeHUh?=
HCC1143 M3\1UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTZTWM2OD1{LkS1N|Y5KM7:TR?= M3Lue3NCVkeHUh?=
LOXIMVI MkTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH2w[plKSzVyPUKuOlAzOSEQvF2= MlXuV2FPT0WU
TE-10 NG\tdnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUX5SXNoUUN3ME2yMlcxQDN6IN88US=> MV3TRW5ITVJ?
NCI-H1882 M4foRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHudYJKSzVyPUKuO|UzOjdizszN MV;TRW5ITVJ?
CHP-126 NGrIUpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkG5TWM2OD1{Lke2N|E4KM7:TR?= NGfqbpVUSU6JRWK=
NCI-H1623 NV3hbm9PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULZZmd7UUN3ME2yMlkzODJ2IN88US=> NHfXS3hUSU6JRWK=
GB-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXOb4RKSzVyPUKuPVM1ODRizszN M2ryUnNCVkeHUh?=
RCC10RGB M4rJWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1O1c2lEPTB;Mj65OVI5OSEQvF2= NUK1Uo02W0GQR1XS
NCI-H2141 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTJwOU[4PVYh|ryP MUfTRW5ITVJ?
GI-ME-N NI\leZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF22TXpKSzVyPUOuNFA2PjVizszN M3K3SnNCVkeHUh?=
NCI-H526 NYnzSVZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGq4RYlKSzVyPUOuNFQxQDVizszN NX\EbIdvW0GQR1XS
NCI-H747 MnP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7wTlBIUUN3ME2zMlA1QTl{IN88US=> M1vtbHNCVkeHUh?=
SNU-423 NGHiWY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzsOolNUUN3ME2zMlIxOzF|IN88US=> MmK1V2FPT0WU
A427 MlLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfOW4xKSzVyPUOuNlU3QTlizszN MlL2V2FPT0WU
CAL-12T MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzyTWM2OD1|LkSwO|E{KM7:TR?= Ml3OV2FPT0WU
LU-99A NHHwXVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLZTIxKSzVyPUOuOFcyODVizszN NIfjWVJUSU6JRWK=
MS-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTNwNUO0Nlkh|ryP NWrrPGoxW0GQR1XS
SK-LU-1 NXXYNXhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF:yWWdKSzVyPUOuO|YzQTVizszN MX\TRW5ITVJ?
SW837 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7KTWM2OD1|Lke2N|M{KM7:TR?= NYHhbXNZW0GQR1XS
ES8 M{\HPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVmxOVBqUUN3ME2zMlg{QDd5IN88US=> M3PVVXNCVkeHUh?=
MZ2-MEL MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\XfIxqUUN3ME2zMlkzODh4IN88US=> MWfTRW5ITVJ?
TGW NVXtV292T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mon4TWM2OD12LkCxN|EyKM7:TR?= M{nwd3NCVkeHUh?=
GP5d MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnsSlFvUUN3ME20MlA2OzZ{IN88US=> MlP4V2FPT0WU
BB49-HNC Mn3NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnP0TWM2OD12LkG1NlE{KM7:TR?= MnHHV2FPT0WU
NB13 MlTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2L6SWlEPTB;ND6yOlg5PyEQvF2= NXnDSXQ3W0GQR1XS
NTERA-S-cl-D1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HGc2lEPTB;ND6yPFYyPSEQvF2= MV7TRW5ITVJ?
NCI-H1648 M1;tNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{naeGlEPTB;ND6yPVgyQSEQvF2= MX;TRW5ITVJ?
LCLC-103H NHn5bohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYiyVplGUUN3ME20MlMzOTl3IN88US=> M4HHVHNCVkeHUh?=
LS-411N NFnlTlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XFU2lEPTB;ND60OFg5PSEQvF2= NXjxTVRTW0GQR1XS
NCI-H1092 MkLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIj0d2NKSzVyPUSuOFU3QDdizszN M4G5[HNCVkeHUh?=
PANC-10-05 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3KWYlKSzVyPUSuOlk5PCEQvF2= NGjTcI9USU6JRWK=
DK-MG NU\NZ296T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljqTWM2OD12LkiwPVM{KM7:TR?= M4PGdnNCVkeHUh?=
OVCAR-5 NFLIcZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXsTWM2OD12LkixNlI3KM7:TR?= NGCzbVdUSU6JRWK=
CAL-39 MmTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7SN3dKSzVyPUSuPFc3PyEQvF2= MnrvV2FPT0WU
TE-441-T NXLmOFVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moj4TWM2OD12LkmwOVM4KM7:TR?= M3P5[HNCVkeHUh?=
MOLT-16 MmjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jtWmlEPTB;ND65OVI2OyEQvF2= M1XmUHNCVkeHUh?=
MCF7 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTvZZJkUUN3ME21MlE1PTF5IN88US=> MlnjV2FPT0WU
CAPAN-1 NILxbldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTVwMkW3NFch|ryP MXTTRW5ITVJ?
PSN1 NWLUfGRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTVwMkeyN|Uh|ryP NVmzcolHW0GQR1XS
NCI-H292 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjTOHpKSzVyPUWuN|AxPDRizszN NEDMOFhUSU6JRWK=
CPC-N NHHoT4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV22VpVrUUN3ME21MlM6PDF7IN88US=> M{fNWHNCVkeHUh?=
DoTc2-4510 MmTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPiUIlKSzVyPUWuOFU{PzFizszN MnfaV2FPT0WU
LB1047-RCC MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTVwNUW5N|Mh|ryP NUS5VYVbW0GQR1XS
MHH-ES-1 MleyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vEVWlEPTB;NT61PVkxPyEQvF2= NFO1U3BUSU6JRWK=
NMC-G1 NIT5W5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3m0dmlEPTB;NT63NFIzPyEQvF2= MoXsV2FPT0WU
SW1710 M1rke2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYr3bphPUUN3ME21Mlc1PzVzIN88US=> MnvSV2FPT0WU
YAPC NHvZU25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XPUmlEPTB;NT63OlIxOSEQvF2= NILjbIhUSU6JRWK=
22RV1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLFTWM2OD13LkiwNFE6KM7:TR?= MXLTRW5ITVJ?
COLO-679 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzwTWM2OD13Lki4PVQ5KM7:TR?= NYjaUmdZW0GQR1XS
TCCSUP MmnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTVwOUOyOVkh|ryP MnrBV2FPT0WU
C2BBe1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTVwOUO5O{DPxE1? M4rDNXNCVkeHUh?=
TE-15 NWSyWox4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjZUXp7UUN3ME22MlA3PjB3IN88US=> MnrUV2FPT0WU
SCLC-21H NYXyU2dUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPxcGFjUUN3ME22MlExQDR|IN88US=> MXjTRW5ITVJ?
EoL-1-cell MlTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{L0bmlEPTB;Nj6xOlU3OyEQvF2= MnfqV2FPT0WU
NKM-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTZwMU[3NUDPxE1? MVLTRW5ITVJ?
NCI-H1304 M1XWV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTZwMke0Nlgh|ryP NE\FfJpUSU6JRWK=
NB6 NH3Z[5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTZwMkm2NlIh|ryP MWrTRW5ITVJ?
NALM-6 M{nUZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LyNmlEPTB;Nj6zN|I{KM7:TR?= NULpVIJ6W0GQR1XS
NCI-H522 M2TMWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2O2S2lEPTB;Nj6zN|MxPiEQvF2= NXjtOJRCW0GQR1XS
MV-4-11 MnLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;odXdUUUN3ME22MlM4ODd7IN88US=> MXHTRW5ITVJ?
LB2241-RCC Mlr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PUR2lEPTB;Nj6zPFY3PyEQvF2= NWPNSGFFW0GQR1XS
NCI-H1417 NX76WllXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTZwNEC4OFch|ryP NX3rTnZQW0GQR1XS
HT-1197 NHn4XGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1m0T2lEPTB;Nj61O|EzOiEQvF2= NVrsTGFpW0GQR1XS
P30-OHK MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfLTHBQUUN3ME22MlYzPzdizszN NUDrO3ByW0GQR1XS
ALL-PO MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{e2bGlEPTB;Nj63NVkyPiEQvF2= NGTyXnJUSU6JRWK=
OVCAR-4 NH7OUlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjhOIlKSzVyPU[uO|U1ODVizszN NWjVWWZ{W0GQR1XS
HCC2157 NF7aRZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;4No5KSzVyPU[uO|c1PzVizszN MnnxV2FPT0WU
NCI-H838 NG\1dodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTZwOU[0PUDPxE1? NFXvUHlUSU6JRWK=
NCI-H1299 NWTFVlF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPjPJVKSzVyPU[uPVcxQSEQvF2= NGfmUFFUSU6JRWK=
SW954 Mn\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HxPGlEPTB;Nz6yNFA3QCEQvF2= MULTRW5ITVJ?
NCI-H441 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXwSnVKSzVyPUeuN|QxPjVizszN MXjTRW5ITVJ?
SK-MEL-2 NVyy[ZJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVe2S4lsUUN3ME23MlQ5Ozd|IN88US=> MULTRW5ITVJ?
KARPAS-45 M2DWPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrQd4ZKSzVyPUeuOlU6OjlizszN NVnWSG5TW0GQR1XS
CAL-54 M3HJTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTdwOEK5O|ch|ryP NFHwZo5USU6JRWK=
KYSE-180 NWiyRoxCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmS5TWM2OD15Lki4PVQyKM7:TR?= NHG2[IdUSU6JRWK=
NCI-H187 NX\RVVZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jIU2lEPTB;Nz65OVk1PyEQvF2= MmnRV2FPT0WU
RT-112 NU[xVpdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRThwMEm2O|ch|ryP NGLhVnRUSU6JRWK=
NCI-H1437 MkSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jVT2lEPTB;OD6wPVc6PSEQvF2= NIL4UXlUSU6JRWK=
SNU-449 NWPZSVNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTTSZlOUUN3ME24MlI5Ojd{IN88US=> NIrZZldUSU6JRWK=
HCC1187 MnPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPzTWM2OD16LkK5N|kyKM7:TR?= MX3TRW5ITVJ?
NCI-H2030 NX;RVYpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRThwM{e3NVQh|ryP M33YZ3NCVkeHUh?=
HuO-3N1 M3eybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVT2cFdOUUN3ME24MlM4QDR2IN88US=> M1\WVHNCVkeHUh?=
COLO-792 M{H1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TaXmlEPTB;OD60NVUzPyEQvF2= MnPmV2FPT0WU
MIA-PaCa-2 Ml;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml30TWM2OD16Lki1OVA5KM7:TR?= Mo[5V2FPT0WU
SK-N-FI M17ORmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkm2TWM2OD17LkC0NlUh|ryP MYDTRW5ITVJ?
MMAC-SF NYjkN3Z7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXIdoJKSzVyPUmuNFk4PTFizszN M13oSHNCVkeHUh?=
NCI-H28 NWqzTYwyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVy2OWo4UUN3ME25MlExPDZ7IN88US=> MWPTRW5ITVJ?
ETK-1 NEXxVJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjmZmlKSzVyPUmuNlk6PzRizszN NVvDb4dmW0GQR1XS
NCI-H1993 NEHSdGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXn6c213UUN3ME25MlQ1OjZzIN88US=> MXLTRW5ITVJ?
no-11 Mor4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PmOmlEPTB;OT60O|EzKM7:TR?= MnvZV2FPT0WU
ChaGo-K-1 NIq2blRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHJb4RKSzVyPUmuOVE2QDNizszN NU\6NGtlW0GQR1XS
NCCIT NYHzZpVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHlTWM2OD17LkWzNVY6KM7:TR?= NXPqfohtW0GQR1XS
SAS M{PlN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUe0dm14UUN3ME2xNE4zPDhizszN NH30TnlUSU6JRWK=
A673 NV\UUIh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;oXmlEPTB;MUCuN|cxPCEQvF2= MnPvV2FPT0WU
NCI-H1522 M2fLeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NED2WIVKSzVyPUGwMlM4ODdizszN Mmn4V2FPT0WU
NCI-H810 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fjN2lEPTB;MUCuN|kxPyEQvF2= NEj3U2VUSU6JRWK=
IST-MES1 NYf3ZYd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjzPGFKSzVyPUGwMlQ2PjRizszN NF23RZVUSU6JRWK=
GR-ST NWnvd45WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHT5WIJKSzVyPUGwMlUxOjRizszN NGTHTXdUSU6JRWK=
SUP-T1 M4Dub2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXiUVBDUUN3ME2xNE44OzF5IN88US=> NYXx[VV3W0GQR1XS
NB5 M{\Hemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHRTWM2OD1zMD65NFIzKM7:TR?= NVTtfI5sW0GQR1XS
MZ1-PC NHjTO49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH2xN|VKSzVyPUGwMlk2PzFizszN MUfTRW5ITVJ?
SK-CO-1 NYGxW4c{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjp[oNKSzVyPUGwMlk6OzFizszN NYSzRoc1W0GQR1XS
Capan-2 MnPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPOSnlbUUN3ME2xNU4{OTl6IN88US=> NG\LdVFUSU6JRWK=
697 NUXkZW9KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPiZ|BFUUN3ME2xNU43PzV5IN88US=> MVnTRW5ITVJ?
REH NWD6T41ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTFzLke0OVEh|ryP NWHTSnlPW0GQR1XS
GI-1 M3PtPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvtRphKSzVyPUGxMlg3OTVizszN MojyV2FPT0WU
BB65-RCC MlO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXSdVRKSzVyPUGyMlA6OTZizszN NUPaR28zW0GQR1XS
NCI-H1651 NXTQe5hDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33XS2lEPTB;MUKuNlQ4QCEQvF2= M{TpRnNCVkeHUh?=
NCI-H1618 MnLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3Oye2lEPTB;MUKuN|k4PiEQvF2= NIT6PWZUSU6JRWK=
NCI-H2081 NFL3RZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3JbYtDUUN3ME2xNk43OTRzIN88US=> MlzYV2FPT0WU
GCIY M12w[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHwTWM2OD1zMj63NlE{KM7:TR?= NFq4[YlUSU6JRWK=
NY M{HOPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTRflVKSzVyPUGzMlA3PDNizszN NIm1WohUSU6JRWK=
PANC-03-27 M2TDOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M123OWlEPTB;MUOuNFgxPyEQvF2= NH[5[GhUSU6JRWK=
BHY MoDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTF|LkKxNlEh|ryP NIG3VlRUSU6JRWK=
SK-OV-3 MlfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2C2bGlEPTB;MUOuN|c3OyEQvF2= M4nhN3NCVkeHUh?=
5637 MkXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTF|Lke3OVkh|ryP NVfLR4ZnW0GQR1XS
LC-1F NILXOZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnQTWM2OD1zND6wN|U3KM7:TR?= MYjTRW5ITVJ?
SNB75 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX:yZWpLUUN3ME2xOE4xOzh|IN88US=> NWXsWYRUW0GQR1XS
CHP-212 NEKyO|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknqTWM2OD1zND6wOFY1KM7:TR?= MXvTRW5ITVJ?
HT-1376 M4OzT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjQfmhRUUN3ME2xOE4yOTJ4IN88US=> NUDBdnN7W0GQR1XS
MONO-MAC-6 NYPBZ2Z4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTF2LkG1NFIh|ryP NYfRRnR7W0GQR1XS
CA46 NW\RVJh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjC[5RKSzVyPUG0MlE5OjdizszN M1nSUXNCVkeHUh?=
SCC-15 NVK5[VNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfINmhKSzVyPUG0MlU2QDNizszN MUTTRW5ITVJ?
ATN-1 MkLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mli3TWM2OD1zND62OlI4KM7:TR?= NFzFN3RUSU6JRWK=
NCI-H2405 NG\R[nVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVz4SYpNUUN3ME2xOE45OTV5IN88US=> MkLvV2FPT0WU
NCI-H716 NVXUO3k1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7Lc3NOUUN3ME2xOE45PDl|IN88US=> M1;oTHNCVkeHUh?=
SW620 MofuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofjTWM2OD1zND65NFE1KM7:TR?= M2jOV3NCVkeHUh?=
NCI-H226 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVWwNGMyUUN3ME2xOE46ODh3IN88US=> MkDhV2FPT0WU
SW962 MlnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfYRplKSzVyPUG0Mlk1OzJizszN NFn1c2dUSU6JRWK=
KYSE-150 MoLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHuTWM2OD1zND65OVUh|ryP MmfXV2FPT0WU
OCUB-M NEj1S2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHm1[XdKSzVyPUG0Mlk5QDNizszN NX;ncHBtW0GQR1XS
ES7 NF;aS4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{D1TmlEPTB;MUWuNFk5PCEQvF2= MlTNV2FPT0WU
SW1463 NXTuUXVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGraSItKSzVyPUG1MlQzOjNizszN MUTTRW5ITVJ?
CAKI-1 NE[5U4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojpTWM2OD1zNT61N|Q3KM7:TR?= NIC0OFJUSU6JRWK=
MKN28 MojwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjKfFdnUUN3ME2xOU42PDd7IN88US=> MU\TRW5ITVJ?
SW13 M{TEe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDjUmRKSzVyPUG1MlYyQCEQvF2= MmTWV2FPT0WU
A3-KAW NEXRcXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\LTWM2OD1zNT65Olk4KM7:TR?= M3HGVXNCVkeHUh?=
LU-65 NXzHOIIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLBTWM2OD1zNT65O|Y5KM7:TR?= MmjCV2FPT0WU
Calu-1 NV7OTGhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LzTWlEPTB;MU[uNFM3QCEQvF2= NI\KSmZUSU6JRWK=
ST486 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDoTWM2OD1zNj6wOFMyKM7:TR?= MlzCV2FPT0WU
BB30-HNC M3\obmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7VWJRKSzVyPUG2MlEzPDZizszN M{fUTnNCVkeHUh?=
EGI-1 M{HBSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\y[mx{UUN3ME2xOk41PDZizszN MmmwV2FPT0WU
SH-4 NF;5WYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULZNlc4UUN3ME2xOk41PzNzIN88US=> MWTTRW5ITVJ?
MN-60 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLZTWM2OD1zNz6yNlk4KM7:TR?= MkjMV2FPT0WU
MPP-89 NIDKTIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTF5LkK0OVkh|ryP NFnJNYlUSU6JRWK=
A2780 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUj6OnlsUUN3ME2xO{41OTN7IN88US=> MneyV2FPT0WU
Daoy MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlz3TWM2OD1zNz60Olk2KM7:TR?= MkWxV2FPT0WU
NCI-H2126 M4Pxb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHYTYtkUUN3ME2xO{41PzdzIN88US=> M2LyVXNCVkeHUh?=
NCI-H1563 MkPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXqV2hvUUN3ME2xO{41QTF5IN88US=> M3TiSXNCVkeHUh?=
8-MG-BA Mnj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTF5Lk[2OFgh|ryP Mm\XV2FPT0WU
786-0 NV[3WGJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHTepdzUUN3ME2xO{45OzV|IN88US=> NYDMPVRWW0GQR1XS
AM-38 NGDBR3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPJTWM2OD1zNz65N|A3KM7:TR?= NUS0TGR[W0GQR1XS
COLO-824 MlvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4O4dmlEPTB;MUiuOFQ{PiEQvF2= MnrnV2FPT0WU
SK-MEL-30 NETpXmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHoPI5KSzVyPUG4MlUxQDJizszN Ml\XV2FPT0WU
CESS NET6cHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLxTWM2OD1zOD63OlA6KM7:TR?= NYTpcYhxW0GQR1XS
BL-70 M2rwdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TVTGlEPTB;MUiuPFE2PiEQvF2= M3jORnNCVkeHUh?=
NCI-H2170 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DpXGlEPTB;MUiuPVE4QSEQvF2= NI\WeGtUSU6JRWK=
HT-3 NWi2VnJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVziS5ZbUUN3ME2xPE46QDNizszN MoXaV2FPT0WU
BOKU MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PRcmlEPTB;MUmuNFM5OSEQvF2= NWW5Onl4W0GQR1XS
HPAF-II NWi5V|Q1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnj2TWM2OD1zOT6zNFE2KM7:TR?= NXLMNotxW0GQR1XS
KGN Mo[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\ITWM2OD1zOT60O|Y2KM7:TR?= M2\LSnNCVkeHUh?=
MC-CAR M{TBW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mny0TWM2OD1zOT62N|E{KM7:TR?= NV30WokzW0GQR1XS
BHT-101 NIG0[|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4OycGlEPTB;MUmuO|c4KM7:TR?= NGPqd2JUSU6JRWK=
SW1783 MlzIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIWwOmxKSzVyPUG5Mlc5ODZizszN NEjQfGlUSU6JRWK=
KP-N-YN MkGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rPTGlEPTB;MkCuNFI3OiEQvF2= Mke1V2FPT0WU
LU-165 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTJyLkW1O|Eh|ryP NEG3bZBUSU6JRWK=
GOTO NGTTb|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHDUGxKSzVyPUKwMlY1PTFizszN NFnCUlFUSU6JRWK=
EFM-19 NHzPWYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DGOWlEPTB;MkGuNFcyPiEQvF2= NG[3NYJUSU6JRWK=
CTV-1 NFXtc2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTJzLkGwOVQh|ryP M37HenNCVkeHUh?=
HEL MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPsTWM2OD1{MT60NlE3KM7:TR?= MkTSV2FPT0WU
SNU-C2B MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTJzLkSyOkDPxE1? NFu1UYFUSU6JRWK=
ECC4 MnTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmH5TWM2OD1{MT63NFch|ryP MlLiV2FPT0WU
NEC8 NXHac5M4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEW1VnRKSzVyPUKxMlg{PjhizszN NHrKTphUSU6JRWK=
KMOE-2 NV[5TJNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTJzLki5NlEh|ryP Mle5V2FPT0WU
NCI-H524 NI\lN2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvNOo9RUUN3ME2yNk4xQDB6IN88US=> NYfZNItGW0GQR1XS
WSU-NHL NHTSXGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXQ[lU6UUN3ME2yNk4yPTd5IN88US=> M{LQfHNCVkeHUh?=
SF126 NEPDe3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3vWZEyUUN3ME2yNk4zPDZ7IN88US=> NWr6emxKW0GQR1XS
HOP-92 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYS2cHE4UUN3ME2yNk4{OTZ5IN88US=> NWqySIhIW0GQR1XS
CTB-1 M2TLemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTKbVFKSzVyPUKyMlQ3PzdizszN M{fzPXNCVkeHUh?=
KYSE-270 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTJ{LkmzOVch|ryP MYfTRW5ITVJ?
SK-MEL-24 NIDFe|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTJ|LkG4O{DPxE1? MX3TRW5ITVJ?
Calu-3 M1vhXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkm1TWM2OD1{Mz6yNVI5KM7:TR?= M1;oeHNCVkeHUh?=
GAMG NYDNRnVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrpU21DUUN3ME2yN{4zOzZ5IN88US=> NHrMWmlUSU6JRWK=
SW1573 M4fn[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLwc285UUN3ME2yN{44PDF3IN88US=> MXnTRW5ITVJ?
MHH-NB-11 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfNZ2RlUUN3ME2yOE4xOTl2IN88US=> NHfVS3FUSU6JRWK=
TK10 NV63NZE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPxTWM2OD1{ND61NFE{KM7:TR?= MY\TRW5ITVJ?
LB373-MEL-D MmO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljPTWM2OD1{ND62NFY1KM7:TR?= MXXTRW5ITVJ?
KALS-1 MmLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HhR2lEPTB;MkSuO|MzPyEQvF2= NGPndoxUSU6JRWK=
HUTU-80 NV72dIY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTJ3LkiwN|Ih|ryP NFTCfodUSU6JRWK=
HuP-T3 NUDzbFkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DBWmlEPTB;Mk[uNVY4PCEQvF2= NVPt[XlLW0GQR1XS
OE19 MnHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTJ4LkKxOVMh|ryP MX7TRW5ITVJ?
J82 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2n3ZWlEPTB;Mk[uNlQ4OSEQvF2= MoP5V2FPT0WU
DU-4475 M4TIdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTqNVZbUUN3ME2yOk4{QDF7IN88US=> NXvMV4RnW0GQR1XS
DMS-53 NH\VNo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHrTWM2OD1{Nj61NVM5KM7:TR?= MkfNV2FPT0WU
COLO-741 M33uPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrkO5hKSzVyPUK2Mlg{PDRizszN M2fp[XNCVkeHUh?=
SW48 NEnLcGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHrTWM2OD1{Nj64PFIh|ryP NHvZbHRUSU6JRWK=
IGR-1 NYjVT2puT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnhOYZKSzVyPUK2Mlk{OzRizszN NIfL[Y1USU6JRWK=
639-V M{XKZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mli5TWM2OD1{Nz6wNlQ2KM7:TR?= NXe4WoUzW0GQR1XS
LK-2 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13qTmlEPTB;MkeuOFE1OSEQvF2= NX;zbJpLW0GQR1XS
NCI-H2347 MnexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3v6[WlEPTB;MkeuPVY6QSEQvF2= MWrTRW5ITVJ?
NCI-H2228 Ml[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoD5TWM2OD1{OD6wPVA2KM7:TR?= Ml;pV2FPT0WU
LS-123 NHX1cW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jWRmlEPTB;MkiuNVI3OiEQvF2= NGjxZVVUSU6JRWK=
U031 NFL1cpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1ixdWlEPTB;MkiuNlUzKM7:TR?= NID2dldUSU6JRWK=
NCI-H1792 NUC1OZdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjGV4pOUUN3ME2yPE41PzJzIN88US=> M4\RfnNCVkeHUh?=
NCI-H2087 M3HBbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTJ6Lke1OVIh|ryP M{CzXnNCVkeHUh?=
NCI-H2342 M3XNeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF:xbVRKSzVyPUK5MlUzODhizszN NXWxVohFW0GQR1XS
SW626 NVy0SHA{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTJ7Lke1OkDPxE1? NHTrO2lUSU6JRWK=
LB2518-MEL MmHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHHTWM2OD1{OT64NVUh|ryP M3TCR3NCVkeHUh?=
RXF393 NXHz[XR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzBUJlWUUN3ME2zNE4xQTV{IN88US=> Mny4V2FPT0WU
LC4-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYf0[I8{UUN3ME2zNE4{ODl{IN88US=> MYfTRW5ITVJ?
NCI-H1694 M{L4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3G3d2lEPTB;M{CuOlYzPCEQvF2= MXvTRW5ITVJ?
K5 MnLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\nT|ZPUUN3ME2zNE46PzB{IN88US=> MVrTRW5ITVJ?
HDLM-2 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TsZ2lEPTB;M{CuPVczPSEQvF2= M321SHNCVkeHUh?=
BCPAP NEnVWmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rpUWlEPTB;M{GuPFM4QSEQvF2= NFzjcXFUSU6JRWK=
BC-3 M4PPeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\LRY1KSzVyPUOyMlE1ODNizszN MoHrV2FPT0WU
LB996-RCC MlfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHsd4VKSzVyPUOyMlI{PThizszN MmXzV2FPT0WU
NCI-H2009 NYS1T|U6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrUZnpKSzVyPUOyMlQ6QDFizszN NX7Q[VF3W0GQR1XS
HTC-C3 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTN|Lke1NVkh|ryP MmH0V2FPT0WU
LAMA-84 MoW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzCcIxmUUN3ME2zOE41PDB5IN88US=> NUHNWGsxW0GQR1XS
CCRF-CEM NWXGcVI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHBVVNUUUN3ME2zOE42PzF3IN88US=> NWHHZWNIW0GQR1XS
AN3-CA NX[3PW5pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLmbWhKSzVyPUO1MlA2PjhizszN NX72flZPW0GQR1XS
NCI-H1734 M{PUd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jCUWlEPTB;M{WuNlU3OSEQvF2= NHzmbW9USU6JRWK=
Ca-Ski MknOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrPTWM2OD1|NT60NVAyKM7:TR?= MVPTRW5ITVJ?
U-266 NH3xN5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEmzUWVKSzVyPUO1MlYyOTRizszN NFPDcG5USU6JRWK=
SBC-5 NG\XOJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37ZNmlEPTB;M{WuO|c5OSEQvF2= NEHtVZpUSU6JRWK=
GT3TKB M4e5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU[yPXhTUUN3ME2zO{4yOTVizszN MWTTRW5ITVJ?
MDA-MB-175-VII MnjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTN5LkKyOFgh|ryP M{DzfXNCVkeHUh?=
PFSK-1 NEe2cZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1GzU2lEPTB;M{euNlQ{PSEQvF2= MXHTRW5ITVJ?
IMR-5 M3\GZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkOxTWM2OD1|Nz6yOFg4KM7:TR?= NVTX[VFVW0GQR1XS
Daudi MojPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4K0[WlEPTB;M{euN|U6PyEQvF2= M3rDVnNCVkeHUh?=
A498 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnL5TWM2OD1|Nz63NlE5KM7:TR?= M1PEWnNCVkeHUh?=
SCC-4 M3nmUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInFW2FKSzVyPUO3Mlc5PDNizszN MnGwV2FPT0WU
COLO-680N NGPwW2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrIOnA3UUN3ME2zPE4zQDh3IN88US=> MkC1V2FPT0WU
SK-MES-1 MkjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XxeGlEPTB;M{iuN|IyPSEQvF2= MXTTRW5ITVJ?
SR MojtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLSTWM2OD1|OD61OFk2KM7:TR?= NVrsNGJ2W0GQR1XS
LNCaP-Clone-FGC M4LRSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnPPItqUUN3ME2zPE42PjN5IN88US=> Mnm4V2FPT0WU
SK-HEP-1 MnjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1[zfmlEPTB;M{iuO|gzOiEQvF2= NXL4R2R6W0GQR1XS
BPH-1 NYj5VYpJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnhTWM2OD1|OD64N|I6KM7:TR?= MkDCV2FPT0WU
NCI-H1755 NVf6fWt5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LDWmlEPTB;M{muOVgyPyEQvF2= NHPhXldUSU6JRWK=
LXF-289 NUfLW49YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3neGFTUUN3ME2zPU45ODh2IN88US=> M1e1cHNCVkeHUh?=
SW1088 NWHadWxRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPqcmZKSzVyPUSwMlIyODdizszN MY\TRW5ITVJ?
MOLT-4 NVXwNZlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTRyLkK5NFEh|ryP MlKxV2FPT0WU
AsPC-1 M3rFNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4CyXGlEPTB;NECuOFU5OyEQvF2= M3vqUXNCVkeHUh?=
HOP-62 MmLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTRyLk[1Olgh|ryP M1r2VnNCVkeHUh?=
A172 M13KbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7RZoZuUUN3ME20NE45PTFzIN88US=> MkDpV2FPT0WU
SN12C MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3udZJKSzVyPUSwMlk{QDVizszN MWDTRW5ITVJ?
MDA-MB-231 NXXnc4RLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTRyLkm4PVgh|ryP M{T0O3NCVkeHUh?=
RPMI-2650 NVvtOGFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPETWM2OD12MT6xOVk{KM7:TR?= M1zESnNCVkeHUh?=
KYSE-140 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjPOYpKSzVyPUSxMlgyOjNizszN NWXJPVR4W0GQR1XS
KINGS-1 M2XIN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLvV21TUUN3ME20Nk41Pjl5IN88US=> M1zJbXNCVkeHUh?=
HSC-3 Mkj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTR{Lk[2OlEh|ryP NXKzdWlUW0GQR1XS
PC-14 MnLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2P2dWlEPTB;NEOuNVg5OiEQvF2= M37YenNCVkeHUh?=
COR-L105 NEHQ[JdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7uTWM2OD12Mz62OVAzKM7:TR?= NF7wcHNUSU6JRWK=
BE-13 NUfUfI0yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rBe2lEPTB;NESuNlM4OSEQvF2= M2nhN3NCVkeHUh?=
NCI-H661 MkmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkm4TWM2OD12ND6yPVU5KM7:TR?= NY\YeHNSW0GQR1XS
IST-MEL1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjGTWM2OD12ND6zOVk6KM7:TR?= NHT6NFVUSU6JRWK=
HCC1806 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7EelBKSzVyPUS0MlU5PzNizszN MX7TRW5ITVJ?
COLO-800 M2LYbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTR2Lki0OVMh|ryP M4jKfnNCVkeHUh?=
IST-SL2 MoLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDGWFdKSzVyPUS1MlEzPDdizszN NWDxe3Q3W0GQR1XS
8305C MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnpO2VtUUN3ME20OU4{ODlizszN M{fFRXNCVkeHUh?=
UACC-62 NXfoUHlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkCyTWM2OD12Nj6yPFc2KM7:TR?= NIrEPXlUSU6JRWK=
COR-L23 NGHXeWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLLN2pVUUN3ME20O{4yQTlizszN NFrmeI9USU6JRWK=
EFE-184 M{XW[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn62TWM2OD12Nz6zPFgh|ryP M3:1cHNCVkeHUh?=
DMS-114 NFjDS49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLJOY4xUUN3ME20O{41OTR7IN88US=> MXjTRW5ITVJ?
KYSE-520 M3jofWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTR6LkWzNVUh|ryP MnnhV2FPT0WU
SNG-M NFyzNYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;NXnRJUUN3ME20PU41OzRizszN M2G3b3NCVkeHUh?=
A2058 M1jzTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH[5SHlKSzVyPUS5MlQ5QDVizszN M4HJNHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo試験 OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the Vmax is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. [1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. [2]
臨床試験 OSI-906 is currently under a Phase III clinical trial in adrenocortical carcinoma (ACC).
特集

プロトコル (参考用のみ)

キナーゼアッセイ: [1]

Protein kinase biochemical assays Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log10 compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerProTM Kinase Selectivity Assay Kit.

細胞アッセイ: [1]

細胞株 MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells
濃度 0.02-0.8 μM
反応時間 3 days
実験の流れ For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only.

動物実験: [1]

動物モデル IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model
製剤 25 mM tartaric acid
投薬量 25 mg / kg and 75 mg / kg
投与方法 Orally administrated at once-daily oral dose for 14 days

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download OSI-906 (Linsitinib) SDF
分子量 421.49
化学式

C26H23N5O

CAS No. 867160-71-2
保管 3年-20℃
2年-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 84 mg/mL (199.29 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 30% PEG 400+0.5% Tween 80+5% Propylene glycol 30mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 (1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutanol

文献中の引用 (15)

Frequently Asked Questions

  • Question 1
    Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?

    Answer: OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related IGF-1R 阻害剤

  • Picropodophyllin (PPP)

    Picropodophyllin (PPP)は一種の選択性的なIGF-1R阻害剤で、IC50値が1 nMです。臨床 1/2です。

  • Erlotinib

    Erlotinibは一種のEGFR阻害剤で、このIC50値が2 nMです。Erlotinibは、EGFRに対する敏感性は人間c-Src或いはv-Abに対する敏感性より1000倍以上が高くなります。

  • R428 (BGB324)

    R428 (BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).

  • Pexidartinib (PLX3397)

    Pexidartinib (PLX3397) is an oral, potent mutil-targeted receptor tyrosine kinase inhibitor of CSF-1R, Kit, and Flt3 with IC50 of 20 nM, 10 nM and 160 nM, respectively. Phase 3.

  • BMS-536924

    BMS-536924は一種のATP競争性的なIGF-1R/IR阻害剤で、このIC50値が100 nM/73 nMです。BMS-536924はMek、FakとLckに適合な抑制活性を表しますが、Akt1とMAPK1/2に抑制活性を殆ど表しません。

  • NVP-AEW541

    NVP-AEW541は一種の有効なIGF-1R/InsR阻害剤で、無細胞実験でこのIC50値が150 nM/140 nMです。NVP-AEW541は無細胞実験の中に、IGF-1Rにもっと高い作用と選択性を表します。

  • NVP-ADW742

    NVP-ADW742は一種のIGF-1R阻害剤で、このIC50値が0.17μMです。NVP-ADW742は、IGF-1Rに作用する効果はInsRに作用する効果より16倍以上が高くなりますが、HER2、PDGFR、VEGFR-2、Bcr-Ablとc-Kitに活性を殆ど表しません。

  • GSK1904529A

    GSK1904529Aは一種の選択性的なIGF-1RとIRの阻害剤で、無細胞実験でこのIC50値が27 nMと25 nMです。GSK1904529Aは、IGF-1R/InsRに作用する選択性はAkt1/2、Aurora A/B、B-Raf、CDK2、EGFR等に作用する選択性より100倍以上が高くなります。

  • BMS-754807

    BMS-754807は一種の有効で、可逆的なIGF-1R/InsR阻害剤で、無細胞実験でIC50値が1.8 nM/1.7 nMです。BMS-754807はMet、Aurora A/B、TrkA/BとRonに作用する効果が少し弱くて、Flt3、Lck、MK2、PKAとPKC等を抑制する活性がありません。臨床2期。

    Features:Muti-inhibitor of the IGR-1R/IR family.

最近チェックしたアイテム

Tags: OSI-906 (Linsitinib)を買う | OSI-906 (Linsitinib)供給者 | OSI-906 (Linsitinib)を購入する | OSI-906 (Linsitinib)費用 | OSI-906 (Linsitinib)生産者 | オーダーOSI-906 (Linsitinib) | OSI-906 (Linsitinib)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ